Safety, Pharmacokinetics, Bioavailability, Food Effect, Drug-Drug Interaction Study of APX001 Administered Orally

NCT02957929 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

46

Enrollment

INDUSTRY

Sponsor class

Conditions

Fungal Infection

Interventions

DRUG: APX001 single IV dose
DRUG: APX001 single oral dose 1
DRUG: APX001 single oral dose 2
DRUG: APX001 single oral dose 3
DRUG: APX001 single oral dose fasted
DRUG: APX001 single oral dose fed
DRUG: APX001 multiple oral doses 1
DRUG: APX001 multiple oral doses 2
DRUG: APX001 multiple oral doses 3
DRUG: Cytochrome P450 substrates
DRUG: Matching placebo control

Sponsor

Basilea Pharmaceutica